Market Pulse Breaking News Alert for Tuesday, April 13, 2010: MZEI -- Medizone International to Greatly Increase Exposure for It
13 Aprile 2010 - 2:30PM
Marketwired
Market Pulse News Alert for this AM, Stocks to Watch are: Medizone
International, Inc. (OTCBB: MZEI), Keryx Biopharmaceuticals Inc.
(NASDAQ: KERX), Ambac Financial Group Inc. (NYSE: ABK) and Palm
Inc. (NASDAQ: PALM).
Investors need to be watching Medizone International, Inc.
(OTCBB: MZEI) this AM! Medizone International is a research and
development company engaged in developing AsepticSure™ System, a
novel ozone-based technology. AsepticSure™ is a portable
decontamination and sterilization system for hospitals, government
buildings, sports training facilities, schools and other critical
infrastructure that might currently require, or need to be prepared
for countermeasures capability from contamination by infectious
biological agents. A government variant is being developed for
bio-terrorism counter measures. Medizone began mockup trials in
January 2010 for both public (hospital) and government
(bio-terrorism countermeasures) applications. In March 2010,
Medizone successful completed the first full round of room scale
testing with its AsepticSure™ sterilization system. Successful
decontamination by AsepticSure™ to the 6 log standard or greater
has been demonstrated with C.difficile, E coli, Pseudomonas
aeruginous, MRSA, VRE and Bacillius subtilis. The AsepticSure™
system is capable of decontamination to the previously unobtainable
6 log standard (99.9999% bactericidal kill) on all hospital
surfaces, hard or soft. Medizone is now able to greatly reduce the
time required to achieve 6 log kills on hard surfaces to 30 minutes
of exposure. From a commercial viewpoint, the higher the "kill
rate" in the shortest turn around time, the more favorably
physicians and hospital administrators will view the system. Given
the outstanding range of bactericidal kill rates Medizone has
achieved to date with the pathogens most often associated with
hospital derived infections, it has become clear there are
opportunities abounding to expand scientific horizons through
collaborative arrangements in many diverse and exciting new
applications. Biological contamination of medical treatment areas
such as hospitals and chronic care facilities has recently been
identified by several world renowned public health institutions,
including the Centers for Disease Control, as one of the greatest
threats to public health and safety in the industrial world.
Hospital Acquired Infections (HAIs) are one of the most common
complications of hospital care. Nearly 2 million patients develop
HAIs, which contribute to 99,000 deaths each year and $28 billion
to $33 billion in health care costs. Demand for an effective
product is huge. Once the trial program for the AsepticSure™
hospital sterilization system is concluded, MZEI expects to
out-source the manufacturing of the product and partner with large,
well established companies that are already fully embedded in their
sector of business as suppliers, such as medical device
manufacturers or service companies. Medizone believes that a field
hardened variant of the AsepticSure™ hospital unit currently being
readied for scale up testing will have wide bio defense
applications internationally as it will be easily deployable in
response to virtually any terrorist assault, extremely effective
against a broad range of lethal pathogens, easy to manage and
maintain and most importantly, it has the potential to save lives.
Medizone now believes that the performance profile of its
AsepticSure™ Sterilization System will exceed all the prerequisite
requirements of affordability, practicability and unmatched
efficacy, which will catapult it into the world market. Medizone
International, Inc. is poised to become a significant player in the
healthcare industry! Medizone International, Inc. just had
excellent news out in a press release before today's opening bell
announcing they are planning to greatly increase the exposure for
its phenomenal product AsepticSure™! This could be great news for
investors!
Medizone International, Inc. (OTCBB: MZEI) announces it will be
attending the Accredited Members, Inc. conference being held at the
Green Valley Ranch Resort in Las Vegas, Nevada between April 20th
and 22nd. Accredited Members sponsors a number of conferences each
year, which interface emerging companies such as Medizone
International with previously qualified high net worth accredited
investors looking for new opportunities.
Edwin Marshall, Medizone's CEO and Board Chairman who will be
attending, commented, "I am pleased to have been invited to this
conference and enthused about the opportunity to showcase Medizone
and our AsepticSure™ technology to an estimated three hundred
qualified investors at one time. As we are about to start our
hospital beta test program, we must also look forward to our
projected capital requirements for entering production and sales
later this year. I believe by attending this conference and the
Vail conference scheduled for June 7-9, it is likely we will be
able to fully fund all of our needs through initial production."
Mr. Marshall went on to say, "Another bonus to the conference is
the opportunity to be introduced to the global audience of Don
Baillargeon's MoneyTV show, as he will be filming a segment of the
show at the conference. MoneyTV has been on the air for more than
14 years and over 650 episodes. They have a global distribution of
170 million TV households. The US distribution is more than 70
million TV households. My personal opinion is that our stock price
is currently significantly undervalued. I expect our presence at
the upcoming conferences in Las Vegas and Vail, combined with being
on MoneyTV, will greatly increase the number of eyes on Medizone
and our phenomenal product, AsepticSure™."
Medizone International, Inc. is a research and development
company engaged in developing its AsepticSure™ System to
decontaminate and sterilize hospital surgical suites, emergency
rooms, intensive care units, schools and other critical
infrastructure. A government variant is being developed for
bio-terrorism counter measures. Research is conducted at Medizone's
dedicated laboratories located in Innovation Park, Queen's
University in Kingston, Ontario, Canada.
Stocks in the news and acting well as of late include: Keryx
Biopharmaceuticals Inc. (NASDAQ: KERX), Ambac Financial Group Inc.
(NYSE: ABK) and Palm Inc. (NASDAQ: PALM).
Information contained herein is the opinion of Market-Pulse.com
("MP") and is intended to be used strictly for informational
purposes. You should be aware that MP attempts to assure itself of
the accuracy of the information contained in the analyses it
publishes. In this regard, MP does, at times, rely on the accuracy
of information supplied to it by the companies which are the
subject of MP's analyses and/or parties related to those companies.
MP also relies on the accuracy and integrity of information that is
contained in company press releases and reports filed with the SEC.
The companies mentioned in this publication have not approved the
content or timing of the information being published unless
otherwise noted.
MP, because it relies on information supplied by various third
parties disclaims any responsibility for the accuracy of such
information. Any investor considering making an investment in any
security which has been the subject of a MP analysis or opinion
should, before making any such investment, consult with his/her
market professional and/or do his/her own independent research
regarding the company which is the subject of an MP opinion,
recommendation or analysis. Information regarding companies which
MP has opined upon is normally available from many sources
including the subject company's filings with the SEC and various
press releases issued by the company.
You should be aware that MP is often compensated for issuing
analyses, recommendations or opinions concerning particular
companies. Its opinion is therefore not unbiased and you should
consider this factor when evaluating MP's statements regarding a
company. MP has been compensated five thousand dollars from
Medizone International, Inc. In addition, MP was also compensated
two hundred fifty thousand restricted shares of Medizone
International, Inc. by the company. MP's officers and directors
reserve the right to buy additional shares of the companies
discussed in this opinion and may profit in the event those shares
rise in value. When MP receives shares as compensation for a
profiled company, MP may sell part or all of any such shares during
the period in which MP is performing such services.
Market-Pulse.com and Market Pulse Breaking News Alert are owned by
Market Pulse LLC.
Contact: Market Pulse 800.290.8935 Email Contact
Grafico Azioni AMBAC (NYSE:ABK)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AMBAC (NYSE:ABK)
Storico
Da Lug 2023 a Lug 2024